Global burden of thyroid cancer in males: a comprehensive analysis of incidence, mortality, and risk factors from 1990 to 2040.
[BACKGROUND] Thyroid cancer incidence has increased globally, with notable gender disparities in epidemiological patterns and outcomes.
- 95% CI 1.64-1.92
APA
Chen H (2026). Global burden of thyroid cancer in males: a comprehensive analysis of incidence, mortality, and risk factors from 1990 to 2040.. Frontiers in oncology, 16, 1699986. https://doi.org/10.3389/fonc.2026.1699986
MLA
Chen H. "Global burden of thyroid cancer in males: a comprehensive analysis of incidence, mortality, and risk factors from 1990 to 2040.." Frontiers in oncology, vol. 16, 2026, pp. 1699986.
PMID
41800040
Abstract
[BACKGROUND] Thyroid cancer incidence has increased globally, with notable gender disparities in epidemiological patterns and outcomes. This study examines the global burden of thyroid cancer in males from 1990 to 2021 and projects trends to 2040.
[METHODS] Using data from the Global Burden of Disease Study 2021, the author analyzed age-standardized incidence, prevalence, deaths, and disability-adjusted life years (DALYs) for thyroid cancer in males across 204 countries and territories. Bayesian meta-regression and ensemble modeling techniques were employed to estimate trends and generate projections.
[RESULTS] Global male thyroid cancer incidence increased from 1.2 to 2.0 per 100,000 (EAPC: 1.78%, 95% CI: 1.64-1.92) between 1990 and 2021, while mortality remained stable (0.4 to 0.5 per 100,000; EAPC: 0.41%, 95% CI: 0.35-0.46). Significant geographical variations were observed, with high-SDI regions showing the highest incidence rates but the most stable mortality patterns. Projections to 2040 indicate continued incidence increases (2.16 per 100,000) with stable mortality (0.45 per 100,000), though uncertainty intervals widen substantially in later years.
[CONCLUSION] The diverging trends between rising incidence and stable mortality in male thyroid cancer suggest substantial, particularly in developing regions. Gender differences in disease characteristics and outcomes highlight the need for sex-specific clinical approaches. These findings emphasize the importance of implementing evidence-based diagnostic practices to minimize overdiagnosis while ensuring appropriate care for advanced cases.
[METHODS] Using data from the Global Burden of Disease Study 2021, the author analyzed age-standardized incidence, prevalence, deaths, and disability-adjusted life years (DALYs) for thyroid cancer in males across 204 countries and territories. Bayesian meta-regression and ensemble modeling techniques were employed to estimate trends and generate projections.
[RESULTS] Global male thyroid cancer incidence increased from 1.2 to 2.0 per 100,000 (EAPC: 1.78%, 95% CI: 1.64-1.92) between 1990 and 2021, while mortality remained stable (0.4 to 0.5 per 100,000; EAPC: 0.41%, 95% CI: 0.35-0.46). Significant geographical variations were observed, with high-SDI regions showing the highest incidence rates but the most stable mortality patterns. Projections to 2040 indicate continued incidence increases (2.16 per 100,000) with stable mortality (0.45 per 100,000), though uncertainty intervals widen substantially in later years.
[CONCLUSION] The diverging trends between rising incidence and stable mortality in male thyroid cancer suggest substantial, particularly in developing regions. Gender differences in disease characteristics and outcomes highlight the need for sex-specific clinical approaches. These findings emphasize the importance of implementing evidence-based diagnostic practices to minimize overdiagnosis while ensuring appropriate care for advanced cases.
같은 제1저자의 인용 많은 논문 (5)
- Autologous Fat Graft for the Treatment of Sighted Posttraumatic Enophthalmos and Sunken Upper Eyelid.
- Elucidating the mechanistic association of xylene inducing non-small cell lung cancer through network toxicology and molecular docking analysis.
- A prognostic signature of ferroptosis and lipid metabolism related genes predicts survival and immunotherapy response in hepatocellular carcinoma.
- The Function of Poly (U) Binding Splicing Factor 60 (PUF60) in Disease Regulation.
- Exploration of In Vivo T-cell Depletion protocols in Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies.